Goldman Sachs Dynamo Strategy Index
|
|
- Mervyn Rogers
- 6 years ago
- Views:
Transcription
1 INDEX INFORMATION Ticker GSDYNMO5 RIC.GSDYNMO5 Thmsn Identifier Index Spnsr Gldman, Sachs & C. Currency USD Number f Underliers max. 8 Vlatility Target 5% Daily Vlatility Cntrl 5.50% Index Calculatr Slactive AG Index Base Date Apr STRATEGY OVERVIEW¹ The ( GSDYNMO5 ): Prvides expsure t cmpnents tracking equities, bnds, rea estate, and cmmdities Seeks t prvide expsure t price mmentum f several asset classes using a methdlgy develped by Gldman, Sachs & C (Index Spnsr) Cmbines 7 underlying cmpnents acrss 4 asset classes and a cash equivalent thrugh a Mney Market Psitin that seeks t capture the highest histrical return amng the universe f underlying cnstituents selected by the Index Spnsr's methdlgy, subject t cnstraints n maximum weights and vlatility cntrls Is rebalanced mnthly and may be rebalanced as frequently as daily if the realized vlatility f the Base Index exceeds the vlatility cap Applies tw levels f vlatility cntrl acrss the prtfli: Target vlatility: 5.0%. It is measured n a mnthly basis and sets a maximum limit n the annualized histric realized vlatility n each mnthly rebalance date Vlatility cap: 5.5%. It is measured n a daily basis. The index is rebalanced whenever the annualized histric realized vlatility f the Base Index exceeds the vlatility cap REBALANCING PROCESS¹ Is calculated n an excess return basis ver the sum f (i) a ntinal cash depsit at Fed Funds, cmpunded daily and (ii) a daily index cst f 0.5% per annum Fr illustrative purpses nly Step 1: Step 2: Step 3: Step 4: On each mnthly rebalance date, test the pssible prtfli cmbinatins f the underliers (cmprised f the 7 cmpnents and the Mney Market Psitin Cnsider nly thse prtflis that have a six mnth realized vlatility f 5.0% r less Of the remaining prtflis, chse the prtfli with the highest six mnth realized return. The weights f the cmpnents in this prtfli will becme the weights in the Base Index On a daily basis, including the mnthly rebalance date, mnitr the realized vlatility f the Base Index ver the past ne mnth. If this vlatility exceeds 5.5%, a pr-rata prtin f the Base Index is allcated t the deleverage psitin (Mney Market Psitin) ¹ The strategy and rebalancing prcess are further described in the full rulebk available at
2 INDEX COMPOSITION ASSET CLASS NAME TICKER MIN WEIGHT MAX WEIGHT Mney Market Mney Market Psitin 0% 100% Equity US Equity Futures Rlling Strategy Index FRSIUSE 0% 30% ishares MSCI EAFE ETF EFA 0% 30% Bnds US Gvernment Bnd Futures Rlling Strategy Index FRSIUSB 0% 60% Eurpean Gvernment Bnd Futures Rlling Strategy Index FRSIEUB 0% 30% Real Estate ishares US Real Estate ETF IYR 0% 30% FTSE EPRA/NAREIT Develped Eurpe Ttal Return Index RPRA 0% 30% Cmmdities Enhanced Strategy E142 ENHG142T 0% 20% INDEX PERFORMANCE VS. INDIVIDUAL ASSET CLASS SPECIFIC ETFs SINCE APRIL 2004² Backtested, Hypthetical Perfrmance; Des nt reflect actual index perfrmance 350% 300% 250% 200% Gldman Sachs Dynam Strategy Index US Bnds (AGG) US Equities (SPY) 150% 100% Jan-2006 Jan-2008 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 ² The values f the individual asset class specific ETFs are ttal return, i.e. ETF dividends are reinvested. The ttal return versins are calculated by Slactive AG. Base Date: Jan Back-testing and ther statistical analysis material that is prvided in cnnectin with the Index use simulated analysis and hypthetical circumstances t estimate hw it may have perfrmed prir t its actual existence. The results btained frm back-testing infrmatin shuld nt be cnsidered indicative f the actual results that might be btained frm an investment r participatin in a financial instrument r transactin referencing the Index. Neither Slactive AG nr Gldman Sachs prvide assurance r guarantee that the prducts linked t the Index will perate r wuld have perated in the past in a manner cnsistent with these materials. The hypthetical histrical levels presented herein have nt been verified by an independent third party, and such hypthetical histrical levels have inherent limitatins. Alternative simulatins, techniques, mdeling r assumptins might prduce significantly different results and prve t be mre apprpriate. Actual results will vary, perhaps materially, frm the simulated returns presented in this dcument. See the Disclaimer Language fr mre infrmatin n Back-testing.
3 COMPOSITION WEIGHTINGS OF THE BASE INDEX RESULTING FROM MONTHLY REBALANCING Current weighting Weighting as f last mnth Enhanced Strategy E % US Equity Futures Rlling Strategy Index 30.0% FTSE EPRA/NAREIT Develped Eurpe Ttal Return Index 3.9% Mney Market Psitin 8.9% US Equity Futures Rlling Strategy Index 30.0% Eurpean Gvernment Bnd Futures Rlling Strategy Index 9.0% Mney Market Psitin 23.1% Enhanced Strategy E % ishares MSCI EAFE ETF 26.9% ishares MSCI EAFE ETF 28.2% FRSIUSE EFA FRSIUSB FRSIEUB IYR RPRA ENHG142T Mney Market Psitin Feb % 26.9% % 23.1% Jan % 28.2% - 9.0% - 3.9% 20.0% 8.9% This rebalancing may cntinue subsequent t the date f this disclsure statement supplement. Rebalancing may affect the perfrmance f the index. HISTORICAL WEIGHTINGS WITHIN THE BASE INDEX³ ROLLING 6-MONTH REALIZED VOLATILITY (p.a.)³ Backtested, Hypthetical Perfrmance; Des nt reflect actual index perfrmance 60% 55% 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% Jan-2006 Jan-2008 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Gldman Sachs Dynam Strategy Index US Bnds (AGG) US Equities (SPY) ³ The values f the individual asset class specific ETFs are ttal return, i.e. ETF dividends are reinvested. The ttal return versins are calculated by Slactive AG. Base Date: Jan Back-testing and ther statistical analysis material that is prvided in cnnectin with the Index use simulated analysis and hypthetical circumstances t estimate hw it may have perfrmed prir t its actual existence. The results btained frm back-testing infrmatin shuld nt be cnsidered indicative f the actual results that might be btained frm an investment r participatin in a financial instrument r transactin referencing the Index. Neither Slactive AG nr Gldman Sachs prvide assurance r guarantee that the prducts linked t the Index will perate r wuld have perated in the past in a manner cnsistent with these materials. The hypthetical histrical levels presented herein have nt been verified by an independent third party, and such hypthetical histrical levels have inherent limitatins. Alternative simulatins, techniques, mdeling r assumptins might prduce significantly different results and prve t be mre apprpriate. Actual results will vary, perhaps materially, frm the simulated returns presented in this dcument. See the Disclaimer Language fr mre infrmatin n Back-testing.
4 STATISTICS⁴ Includes backtested hypthetical perfrmance; may nt reflect actual index perfrmance AS OF JAN Gldman Sachs Dynam Strategy Index US Bnds (AGG) US Equities (SPY) Effective Perfrmance (1M) 1.39% 0.47% 1.21% Effective Perfrmance (6M) 6.34% 1.13% 11.48% Effective Perfrmance (1Y) 9.54% 3.55% 21.71% Effective Perfrmance (3Y) 8.20% 7.80% 37.35% Effective Perfrmance (5Y) 19.34% 11.78% % Perfrmance since Jun 2011 (p.a.)⁴ 3.71% 2.96% 13.77% Perfrmance since Apr 2004 (p.a.)⁴ 4.98% 4.21% 8.83% Vlatility (p.a.) (since Apr 2004)⁴ ⁵ 4.98% 3.74% 18.34% Return ver Risk (since Apr 2004)⁶ Maximum Drawdwn (since Apr 2004)⁷ 8.49% 5.14% 55.18% ⁴ The values f the individual asset class specific ETFs are ttal return, i.e. ETF dividends are reinvested. The ttal return versins are calculated by Slactive AG. Base Date: Jan Back-testing and ther statistical analysis material that is prvided in cnnectin with the Index use simulated analysis and hypthetical circumstances t estimate hw it may have perfrmed prir t its actual existence. The results btained frm back-testing infrmatin shuld nt be cnsidered indicative f the actual results that might be btained frm an investment r participatin in a financial instrument r transactin referencing the Index. Neither Slactive AG nr Gldman Sachs prvide assurance r guarantee that the prducts linked t the Index will perate r wuld have perated in the past in a manner cnsistent with these materials. The hypthetical histrical levels presented herein have nt been verified by an independent third party, and such hypthetical histrical levels have inherent limitatins. Alternative simulatins, techniques, mdeling r assumptins might prduce significantly different results and prve t be mre apprpriate. Actual results will vary, perhaps materially, frm the simulated returns presented in this dcument. See the Disclaimer Language fr mre infrmatin n Back-testing. ⁵ Calculated n a per annum percentage basis. ⁶ Calculated n the same basis as realized vlatility used in calculating the index. ⁷ Calculated by dividing the annualized perfrmance by the annualized realized vlatility since April ⁸ The largest percentage decline experienced in the relevant measure frm a previusly ccurring maximum level. ⁹ Effective Perfrmance is calculated as the pint t pint return ver the perid. Fr the Gldman Sachs Dynam Strategy Index perfrmance statistics: 1M Initial Level = , Final Level = , 6M Initial Level = , Final Level = , 1Y Initial Level = , Final Level = , 3Y Initial Level = , Final Level = , 5Y Initial Level = , Final Level =
5 DISCLAIMER The financial instrument is nt spnsred, prmted, sld r supprted in any ther manner by Slactive AG (the "Calculatin Agent") nr des the Calculatin Agent ffer any express r implicit guarantee r assurance either with regard t the results f using the Index and/r Index trade mark r the Index Price at any time r in any ther respect. The Index is calculated and published by the Calculatin Agent. The Calculatin Agent uses its best effrts t ensure that the Index is calculated crrectly. The Calculatin Agent des nt warrant the accuracy r cmpleteness f any infrmatin cntained herein. Irrespective f its bligatins twards the Issuer, the Calculatin Agent has n bligatin t pint ut errrs in the Index t third parties including but nt limited t investrs and/r financial intermediaries f the financial instrument. The calculatin and publicatin f the Index by the Calculatin Agent fr the purpse f use in cnnectin with the financial instrument des nt cnstitute a recmmendatin by the Calculatin Agent t invest capital in said financial instrument nr des it in any way represent an assurance r pinin f the Calculatin Agent with regard t any investment in this financial instrument. Gldman Sachs des nt warrant the accuracy r cmpleteness f any infrmatin cntained herein and prvides n assurance that this infrmatin is, in fact, accurate. The infrmatin cntained herein is subject t change withut ntice. Any representatins, prjectins and cmparisns cntained herein may nt reflect the pinins f Gldman Sachs and may nt be accurate either nw r at a future date. Cnsequently, yu shuld nt rely n such representatins, prjectins, cmparisns r ther pinins when selecting any investment prduct r making a recmmendatin t a custmer. Current and future ecnmic and ther market events cncerning an investment prduct r an index may cause the infrmatin prvided herein t be incrrect. Past perfrmance is nt indicative f future results and shuld never be relied upn in making an investment decisin r recmmendatin. Any investments r strategies referenced herein d nt take int accunt the investment bjectives, financial situatin r particular needs f any specific persn. Prduct suitability must be independently determined fr each individual investr. Gldman Sachs explicitly disclaims any respnsibility fr prduct suitability r suitability determinatins related t individual investrs Gldman Sachs. All rights reserved. DISCLAIMER LANGUAGE The Gldman Sachs Dynam Strategy Index (the "index") is a mmentum driven strategy, aiming t capture trends in the market by using histrical data ver a predefined hrizn (e.g. 6 mnths). Despite past simulatins, there is n guarantee that the strategy will be able t capture trends effectively, r that the chsen hrizn will still be relevant in the future. There is n guarantee that the index will nt underperfrm sme r all f the underlying assets. In particular, the index may have a significant weight in ne f thse assets at the time f a sudden drp, r n expsure t ne f thse underlyings at a time it has a strng perfrmance. Different indices with a different set f underlying assets may significantly utperfrm the selected index. Fr parts f the backtesting perid, the underlying assets shwed in this presentatin have had strng perfrmances. Backtested and past perfrmance figures are nt a reliable indicatr r guarantee f future results. The index is nt actively managed and GS des nt exercise discretin in cnstructing, calculating r executing the strategy. Fr further infrmatin and disclsure abut the strategy, including relevant risk factrs, please refer t the related transactin dcumentatin. The index was launched n June 15, The US Equity Futures Rlling Strategy Index, the US Gvernment Bnd Futures Rlling Strategy Index and Eurpean Gvernment Bnd Futures Rlling Strategy Index (cllectively, the Underlying Indices ) are the exclusive prperty f Gldman Sachs Internatinal, which has cntracted with S&P Opc, LLC (a subsidiary f S&P Dw Jnes Indices LLC) ( S&P Dw Jnes Indices ) t calculate and maintain the Underlying Indices based n an bjective pre-agreed methdlgy. S&P is a registered trademark f Standard & Pr s Financial Services LLC ( SPFS ); Dw Jnes is a registered trademark f Dw Jnes Trademark Hldings LLC ( Dw Jnes ); and, these trademarks have been licensed t S&P Dw Jnes Indices. Neither S&P Dw Jnes Indices, SPFS, Dw Jnes nr any f their affiliates spnsr and prmte the Index and nne shall be liable fr any errrs r missins in calculating the Index. Gldman Sachs Internatinal has cntracted with STOXX Limited, Zurich, Switzerland ( STOXX ) t maintain and calculate the Eurpean Equity Futures Rlling Strategy Index (the Index ). STOXX and its licensr Dw Jnes & Cmpany, Inc., a Delaware crpratin, New Yrk, USA, d nt have any legal bligatins twards the purchasers f the financial prduct linked t the Eurpean Equity Futures Rlling Strategy Index ( Financial Prduct ) and cannt be held liable fr any lsses r damages which relate t investments in the Financial Prduct. Purchasers f the Financial Prduct are made aware and accept that index calculatins are based n large quantities f data prvided by third parties and are thus susceptible t errrs and delays. This may result in errrs and delays in the Index which may have an impact n the Financial Prduct. ishares is a registered trademark f BlackRck Institutinal Trust Cmpany, N.A. ( BITC ). The index is nt spnsred, endrsed, sld, r prmted by BITC. BITC makes n representatins r warranties t the wners f the index r any member f the public regarding the advisability f investing in the index. BITC has n bligatin r liability in cnnectin with the peratin, marketing, trading r sale f the index. Surce: FTSE Internatinal Limited ( FTSE ) FTSE FTSE is a trade mark f Lndn Stck Exchange Plc and The Financial Times Limited and is used by FTSE under licence. All rights in the FTSE indices and / r FTSE ratings vest in FTSE and/r its licensrs. Neither FTSE nr its licensrs accept any liability fr any errrs r missins in the FTSE indices and / r FTSE ratings r underlying data. N further distributin f FTSE Data is permitted withut FTSE s express written cnsent. Enhanced Strategy E142 is derived and calculated based n the S&P GSCI Index under license frm S&P Dw Jnes Indices LLC ( S&P ). The Enhanced StrategyE142 and/r the Gldman Sachs Dynam Strategy Index is nt spnsred, endrsed, sld r prmted by S&P, its affiliates r its third party licensrs. S&P and its affiliates shall have n liability fr any errrs r missins in the Enhanced Strategy E142. DETAILED HISTORICAL COMPOSITION WEIGHTINGS OF THE INDEX RESULTING FROM DAILY VOLATILITY CONTROL 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Jan Jan Jan Jan Jan Jan Jan Deleverage Psitin (Mney Market Psitin) Base Index
6 DETAILED HISTORICAL MONTHLY PERFORMANCE¹⁰ YEAR JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC ANNUAL % 3.38% % 1.09% -0.11% 0.87% 1.37% -0.58% 1.24% 0.18% 0.90% 1.37% 1.10% 1.39% 9.54% % 0.65% 1.00% -0.60% 0.41% 3.27% -0.41% -1.01% -0.51% -1.92% -0.96% 1.05% 0.80% % 0.31% 0.43% -1.47% -0.87% -1.22% 1.98% -2.27% -0.30% -0.54% -0.43% -1.08% -2.01% % 2.14% -0.57% 1.31% 2.05% 1.01% -0.17% 2.84% -2.48% 1.55% 1.32% 1.60% 10.08% ¹⁰ The values f the individual asset class specific ETFs are ttal return, i.e. ETF dividends are reinvested. The ttal return versins are calculated by Slactive AG. Base Date: Jan Back-testing and ther statistical analysis material that is prvided in cnnectin with the Index use simulated analysis and hypthetical circumstances t estimate hw it may have perfrmed prir t its actual existence. The results btained frm back-testing infrmatin shuld nt be cnsidered indicative f the actual results that might be btained frm an investment r participatin in a financial instrument r transactin referencing the Index. Neither Slactive AG nr Gldman Sachs prvide assurance r guarantee that the prducts linked t the Index will perate r wuld have perated in the past in a manner cnsistent with these materials. The hypthetical histrical levels presented herein have nt been verified by an independent third party, and such hypthetical histrical levels have inherent limitatins. Alternative simulatins, techniques, mdeling r assumptins might prduce significantly different results and prve t be mre apprpriate. Actual results will vary, perhaps materially, frm the simulated returns presented in this dcument. See the Disclaimer Language fr mre infrmatin n Back-testing. DETAILED HISTORICAL COMPOSITION WEIGHTINGS OF THE BASE INDEX RESULTING FROM MONTHLY REBALANCING FRSIUSE EFA FRSIUSB FRSIEUB IYR RPRA ENHG142T Mney Market Psitin Mar % 2.0% 31.8% 2.2% 24.5% 30.0% 5.3% - Apr % 7.9% 22.7% 30.0% 8.1% 13.4% May % % % 13.4% 21.7% Jun % % % 15.0% 28.1% Jul % 1.4% 30.0% 13.8% 35.1% Aug % % 14.8% 26.0% Sep % 3.6% 30.0% 15.7% 20.7% Oct % 1.4% 30.0% 15.7% 26.2% Nv % 30.0% 16.2% 27.4% 12.1% 10.7% Dec % 0.8% 30.0% 19.8% 30.0% 12.4% 2.7% Jan % 3.5% 30.0% 19.2% 30.0% 9.2% - Feb % 3.0% 30.0% 5.3% 30.0% 7.0% - Mar % % % 9.2% 6.2% Apr % % % 10.4% 6.9% May % % % 9.7% 11.6% Jun % 30.0% 4.1% 30.0% 14.6% - Jul % 30.0% % 17.5% 12.5% Aug % 16.8% 15.8% 15.1% 22.3% Sep % 30.0% 6.1% 26.7% 14.1% 18.7% Oct % 5.7% 30.0% 10.6% 30.0% 7.7% 8.2% Nv % - 8.3% 0.4% 30.0% 8.7% 33.6% Dec % % 30.0% 5.1% 39.3% Jan % % 3.2% 39.4% Feb % % 3.0% 43.6% Mar % % 30.1% % Apr % % 28.7% % May % % 23.2% 2.4% 50.7% Jun % % 13.3% 10.8% 60.3% Jul % 9.4% 12.8% 61.3% Aug % 22.3% 3.7% 67.9% Sep % 3.3% 15.5% 60.8%
7 FRSIUSE EFA FRSIUSB FRSIEUB IYR RPRA ENHG142T Mney Market Psitin Oct % 29.6% 8.7% 22.5% - - Nv % 30.0% 17.2% 15.8% - 2.3% Dec % 13.5% 12.6% 23.6% - 8.5% Jan % 2.1% 46.7% - 4.4% 30.0% - 7.6% Feb % 7.8% 11.7% % 30.0% % Mar % % 30.1% - 7.6% Apr % 23.8% % 2.9% 36.0% May % 23.7% % 3.7% 34.9% Jun % 27.3% % Jul % % 59.7% Aug % 59.6% % 0.9% Sep % % % - Oct % % % - Nv % 60.0% % 4.3% Dec % 60.0% 6.0% % 9.8% Jan % % % 12.2% Feb % - 2.9% % 21.8% Mar % - 3.5% % 34.5% Apr % - 3.0% % 29.2% May % - 4.4% % 30.6% Jun % - 4.1% % 51.3% Jul % - 3.2% % 52.3% Aug % - 4.6% % 58.9% Sep % - 5.6% % 24.1% Oct % % Nv % 30.0% % Dec % 30.0% % Jan % 30.0% % Feb % 30.0% % Mar % 30.0% % Apr % 30.0% % May % 30.9% 29.3% 0.0% 0.7% % Jun % 10.4% % Jul % 86.7% Aug % % - 1.7% 1.7% 54.2% Sep % 8.8% 0.9% 30.0% 0.1% 5.6% % Oct % % - 8.8% % Nv % 3.8% 30.0% - 9.1% 3.1% 42.1% Dec % % 30.0% % % Jan % % 30.0% 5.4% 8.0% % Feb % % 30.0% 7.9% 12.0% - - Mar % % 30.0% 11.5% Apr % % 30.0% 8.2% 2.5% % May % % 30.0% 15.2% Jun % 30.0% 19.8% Jul % 30.0% 10.0% Aug % 22.2% 17.8% Sep % 30.0% 19.6% - - -
8 FRSIUSE EFA FRSIUSB FRSIEUB IYR RPRA ENHG142T Mney Market Psitin Oct % 30.0% % - - Nv % 60.0% 17.1% 0.2% 22.0% - - Dec % 60.0% % 4.2% 8.3% Jan % % 3.3% % 5.6% 35.9% Feb % % 1.3% - 3.1% 16.2% 42.1% Mar % - 0.5% % 16.0% 61.3% Apr % % 61.7% May % - 0.6% - 1.2% % 62.4% Jun % % 16.1% 11.6% 25.0% 7.7% 9.4% Jul % 0.8% 23.3% 14.5% 1.4% - Aug % 30.0% 14.7% 30.0% - - Sep % 30.0% 1.7% - 2.6% 5.7% Oct % 60.0% 30.0% % Nv % % 30.0% % Dec % % 29.6% % 0.3% Jan % % 30.1% % - Feb % % 30.0% Mar % % 30.0% Apr % % 30.0% % - May % % 30.0% 22.2% Jun % 30.0% 30.0% 8.8% - - Jul % 30.0% 18.1% 23.0% - - Aug % 30.0% 8.3% 30.0% - - Sep % 30.0% 10.0% 30.0% - - Oct % 30.0% 14.4% 30.0% - - Nv % 60.0% % - - Dec % 55.5% 0.6% % - - Jan % 21.9% 30.0% % 0.4% - Feb % 30.0% % 11.4% - 0.6% 40.4% Mar % 37.3% 15.7% 12.8% 4.1% - - Apr % 14.8% 30.0% 30.0% 8.4% - - May % 21.6% 30.0% 30.0% 3.6% - - Jun % % 4.4% 14.1% % Jul % % % Aug % % % % Sep % % 50.9% Oct % 12.4% % % Nv % 9.3% % 5.9% 54.2% Dec % 11.4% % Jan % 11.4% - 7.3% - 7.0% 8.7% 35.6% Feb % 18.5% 19.5% 30.0% % - 1.0% Mar % % 30.0% % - - Apr % - 7.3% 30.0% % 1.9% 8.4% May % % 2.0% 30.0% 20.0% 4.5% Jun % 30.0% 29.0% 21.9% 11.4% - Jul % 30.0% 30.0% 26.1% 2.9% - Aug % - 3.3% 30.0% 30.0% 21.0% 2.6% - Sep % - 5.2% 30.0% 30.0% 18.3% - -
9 FRSIUSE EFA FRSIUSB FRSIEUB IYR RPRA ENHG142T Mney Market Psitin Oct % - 8.9% 30.0% 1.1% 30.0% - - Nv % % 30.0% 30.0% 18.1% - - Dec % % 30.0% 20.1% 10.0% - - Jan % % 30.0% 30.1% 21.7% - - Feb % 30.0% 18.2% 25.3% - - Mar % % 30.0% 7.3% 30.0% - - Apr % 30.0% 7.9% 26.3% - 7.5% May % % 30.0% % % Jun % 16.9% % % Jul % 13.8% % % Aug % 9.6% % % Sep % % Oct % % Nv % % % Dec % 30.0% % - 5.4% Jan % 30.0% 22.0% 4.9% % Feb % 30.0% % Mar % 30.0% 20.7% Apr % % 30.0% 13.9% May % 30.0% 20.7% Jun % 30.0% 22.3% Jul % 30.0% 9.9% % - Aug % % 30.0% 17.5% Sep % % 30.0% 18.6% - 5.7% - Oct % % 30.0% 9.9% % - Nv % % 30.0% Dec % % % Jan % 20.1% % Feb % % 51.2% Mar % 15.8% % 43.7% Apr % 30.0% % 31.5% May % 24.9% % 0.1% 12.2% - 8.7% Jun % 30.0% 7.0% 19.7% % - - Jul % 30.0% 20.7% - 5.5% 13.8% - - Aug % 30.0% 22.0% % - - Sep % 30.0% 27.2% % - - Oct % 30.0% 21.2% % 3.2% - Nv % 30.0% % % - Dec % 30.0% % 1.5% % - Jan % 28.2% - 9.0% - 3.9% 20.0% 8.9% Feb % 26.9% % 23.1%
Independent Charitable Patient Assistance Program (IPAP) Code of Ethics
Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationAV-07 How to Improve Data Quality and Get Value From Your CMMS. Cecelia Adair Las Vegas Valley Water District
AV-07 Hw t Imprve Data Quality and Get Value Frm Yur CMMS Cecelia Adair Las Vegas Valley Water District Purpse Hw t get mre frm yur maintenance management system Present a methdlgy t imprve data Demnstrate
More informationFor personal use only
Fr persnal use nly ASX / MEDIA RELEASE FOR IMMEDIATE RELEASE 10 May 2013 CROWN RECEIVES NSW GAMING REGULATORY APPROVALS MELBOURNE: Crwn Limited (ASX: CWN) annunced tday that it has received written advice
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationHerbal Medicines: Traditional Herbal Registration
Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality
More informationTELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT
TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT Intrductin This is the Explanatry Statement fr the revised Cmmunicatins Alliance Telecmmunicatins Cnsumer Prtectins (TCP) Industry
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationCode of employment practice on infant feeding
Cde f emplyment practice n infant feeding An Emplyer s guide t: Sectin 69Y f the Emplyment Relatins Act 2000 Frewrd As Minister f Labur, I am pleased t publish the Cde f Emplyment Practice n Infant Feeding.
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationSUMMARY THE EUROPEAN COMMUNITY STRATEGY
SUMMARY THE EUROPEAN COMMUNITY STRATEGY FOR THE PHASEOUT OF CFCS IN MDIS 1. The Eurpean Cmmunity s transitin strategy fr the phaseut f CFCs in metered-dse inhalers (MDIs) was submitted t the Parties t
More informationEMC believes the information in this publication is accurate as of its publication date. The information is subject to change without notice.
EMC DATA PROTECTION ADVISOR (DPA) MIGRATION TECH NOTE With SQL as external database fr t 5.5.1 and later DPA versin 5.x releases t 6.0 SP1 and later ABSTRACT This Tech Nte prvides the steps t migrate frm
More informationSignature Assignment. Course. ANTH 2346: General Anthropology. Assignment ID (to be assigned) Outcomes/Rubrics to be Assessed by the Assignment
Signature Assignment ANTH 2346: General Anthrplgy Outcmes/Rubrics t be Assessed by the Assignment Cmmunicatin Critical Thinking Empirical and Quantitative Reasning Scial Respnsibility Assignment Descriptin
More informationPress Release. Adocia: Activity and results for the first half of 2013
Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More information2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE
2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizatins, Clinical Cascade Breakut Sessin TB/HIV EXERCISE Created by the ICPI TB/HIV Wrkstream Abut this Handut
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationA fake medicine that passes itself off as a real, authorised medicine. (1)
Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces
More informationStatement of Work for Linked Data Consulting Services
A. Backgrund Infrmatin Statement f Wrk fr Linked Data Cnsulting Services The Natinal Library f Medicine (NLM), in Bethesda, Maryland, is a part f the Natinal Institutes f Health, US Department f Health
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationNovel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.
Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute
More informationTrue Patient & Partner Engagement How is it done? How can I do it?
True Patient & Partner Engagement Hw is it dne? Hw can I d it? GROUP TECHNICAL ASSISTANCE JANUARY 18, 2017 COLORADO FOUNDATION FOR PUBLIC HEALTH AND THE ENVIRONMENT Webinar Objectives 1. Describe patient
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationIMMIGRATION Canada. Temporary Resident Visa. Los Angeles and New York City Visa Office Instructions. Table of Contents IMM 5876 E ( )
IMMIGRATION Canada Table f Cntents Dcument Checklist Temprary resident visa Temprary Resident Visa Ls Angeles and New Yrk City Visa Office Instructins This applicatin is made available free by Immigratin,
More informationCode of Conduct for Employees
Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationOntario s Approach to Federal Cannabis Legalization
Ontari s Apprach t Federal Cannabis Legalizatin Ontari s Key Areas f Fcus Ontari s regulatry apprach will align with the federal gvernment s legislative framewrk (see Appendix fr further detail n federal
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationWelcome to Third Party Fundraising Medical University of South Carolina Foundation
Welcme t Third Party Fundraising Medical University f Suth Carlina Fundatin We are hnred yu are cnsidering the Medical University f Suth Carlina (MUSC) as a beneficiary f yur fundraising activities. Charitable
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More informationEDPS 475: Instructional Objectives for Midterm Exam Behaviorism
EDPS 475: Instructinal Objectives fr Midterm Exam Behavirism 1. Given a nvel example t chse frm, identify the characteristics f classical cnditining. General mdel: Stimulus (S) elicits >Respnse (R) Based
More informationA Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013
A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationSmoking Cessation Improvement in SFHN Primary Care,
Smking Cessatin Imprvement in SFHN Primary Care, 2015-16 David Silven, PhD, Supervising Psychlgist, SFHN Primary Care Behaviral Health Ellen Chen, MD, Directr f Quality, SFHN Primary Care Why smking assessment
More informationCoding. Training Guide
Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationPress Release. Adocia Reports Operational and Financial Results for the First Half of 2014
Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationSCALES NW HEARING PROTECTION PROGRAM
PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationWorld Confederation for Physical Therapy Congress , May Singapore
Wrld Cnfederatin fr Physical Therapy Cngress 2015 1-4, May Singapre Call fr applicatins fr Chair f the Internatinal Scientific Cmmittee The Executive Cmmittee f WCPT invites applicatins and suggestins
More informationThe Cannabis Act and Regulations
The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics
More informationIndirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version
Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationAnnual Assembly Abstract Review Process
Annual Assembly Abstract Review Prcess AAHPM and HPNA cllabrate t review and select abstracts fr Annual Assembly. The cmmittees meet prir t the calls t review and update the Assembly bjectives (Planning
More informationImproving Surveillance and Monitoring of Self-harm in Irish Prisons
HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June
More informationSession 5: Is FOOD fair?
Sessin 5: Is FOOD fair? Age range: 7-11 years Outline Learners will play a simulatin game Can yu beat the system?, t develp their understanding f the glbal fd system and its winners and lsers. They will
More information2018 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26
More informationLee County Florida Income Guideline Chart
NEIGHBORHOOD STABILIZATION PROGRAM OF LEE COUNTY BUYER-RELATED QUESTIONS 1. Why is NSP beneficial t yur buyers? Three key advantages make the NSP Prgram especially attractive t eligible buyers: 1) Investrs
More informationFrontier School of Innovation District Wellness Policy
Frntier Schl f Innvatin 6700 Crprate dr. Suite 150 Phne: 816-363-1907 http://www.kcfsi.rg/ Frntier Schl f Innvatin District Wellness Plicy The Bard prmtes healthy schls, by supprting wellness, gd nutritin,
More informationLaw Fellowships in Legal Empowerment
Law Fellwships in Legal Empwerment Abut Namati Namati is dedicated t putting the law in peple s hands. We strive t build a just wrld, in which every ne f us can take part in the decisins and demand accuntability
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationBritish Sign Language (BSL) Plan October 2018 Scottish Charity Regulator
British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public
More informationPost Distribution Monitoring Report
Pst Distributin Mnitring Reprt Hygiene Kit funded by IMC Backgrund Infrmatin Lcatin: Zaatari Camp (All districts) Dates f data cllectin: 1-2 f Octber, 2014 Objective: t understand t what extent the distributin
More informationPET FORM Planning and Evaluation Tracking ( Assessment Period)
Divisin f: Behaviral Studies PET FORM Planning and Evaluatin Tracking (2010 2011 Assessment Perid) Persn Respnsible fr this Divisin: Jerry Mller Department f: Behaviral Sciences Persn Respnsible fr this
More informationWhat should I know about the new TCAP/EOC?
What shuld I knw abut the new TCAP/EOC? Access the TDOE Scial Studies Assessments Page HERE. Frm: http://www.tn.gv/assets/entities/educatin/attachments/tst_summative_assessment_calendar_2015-16.pdf Part
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationTaylors Lakes Hotel. Responsible Gambling Code of Conduct. PVS Pty Ltd Responsible Gambling Code of Conduct page 1 of 12
Taylrs Lakes Htel Respnsible Gambling Cde f Cnduct 2012 Apprved by the VCGLR 27 June 2012 PVS Pty Ltd Respnsible Gambling Cde f Cnduct page 1 f 12 Gaming Venue Respnsible Gambling Cde f Cnduct 1. Venue
More informationCall for evidence on the use of skin sensitisers, skin irritants and corrosive substances in textile and leather articles, hides and furs
Call fr evidence n the use f skin sensitisers, skin irritants and crrsive substances in textile and leather articles, hides and furs Backgrund dcument Backgrund Prductin and prcessing f textile and leather
More informationAnnex E Terms of Reference: Therapeutic use
Annex E Terms f Reference: Therapeutic use The purpse f the pre-review reprt is t synthesize existing scientific evidence abut the therapeutic use and ptential fr dependence and abuse f cannabisrelated
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationEMV. Terminal Type Approval PCD Level 1. Administrative Process. Version 2.6b December 2016
EMV Terminal Type Apprval PCD Level 1 Administrative Prcess Versin 2.6b December 2016 permitted nly pursuant t the applicable agreement between the user and EMVC fund at www.emvc.cm. EMV is a registered
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationParticipation Guide. Section 1: Frequently Asked Questions about Care PAC. Section 2: How to Contribute to Care PAC
Participatin Guide Sectin 1: Frequently Asked Questins abut Care PAC Sectin 2: Hw t Cntribute t Care PAC Sectin 3: Fundraising Activities fr Facilities Sectin 4: Resurces Sectin 1: Frequently Asked Questins
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationFOUNDATIONS OF DECISION-MAKING...
Table f Cntents FOUNDATIONS OF DECISION-MAKING... Errr! Bkmark nt Describe the decisin-making prcess pp.62-66... Errr! Bkmark nt Explain the three appraches managers can use t make decisins pp.67-70 Errr!
More informationCFS Private Sector modalities
CFS Private Sectr mdalities APPROVED September 8, 2011 A. BACKGROUND 1. Fd security exists when all peple at all times have physical and ecnmic access t sufficient, safe and nutritius fd t meet their dietary
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationNutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:
Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin
More informationDISTRIBUTION: ORGANIZATION WIDE APPROVED BY: VP COMPLIANCE
LAST REVISED: Page 1 f 5 POLICY CarePint Health (Baynne Medical Center, Christ Hspital, Hbken University Medical Center, CarePint Health Medical Grup, Garden State Healthcare Assciates, CarePint Health
More informationCatherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support
Catherine Wrthingham Fellws f APTA Instructins fr Writing a Letter f Supprt Fllwing is infrmatin designed t assist persns asked t write a letter f supprt fr a nminee fr the American Physical Therapy Assciatin
More informationState Health Improvement Plan Choosing Priorities, Creating a Plan. DHHS DPH - SHIP Priorities (Sept2016) 1
State Health Imprvement Plan 2017-2021 Chsing Pririties, Creating a Plan DHHS DPH - SHIP Pririties (Sept2016) 1 Creating a Plan: 2017-2021 SHIP Welcme! Wh s here? What is the State Health Imprvement Plan
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationInterpretation. Historical enquiry religious diversity
Name: Year 8 Histry Prject 3: D The Cmmnwealth Games Still Matter In The 21 st Century? Mdule: Date Set: Deadline: Descriptin f the task: The prject is split int three separate parts: The prject is split
More informationMGPR Training Courses Guide
MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More informationCHEAC Summary. BMCR Medical Cannabis Regulations. Distribution, Transportation and Dispensaries
CHEAC Summary BMCR Medical Cannabis Regulatins Distributin, Transprtatin and Dispensaries The Bureau f Medical Cannabis Regulatin (BMCR) prpsed regulatins fcus n the applicatin, licensing, and perating
More informationAUXILIARY AID AND SERVICES PLAN January 2017, Revised- All Rights Reserved
The Salvatin Army f Lee, Hendry, and Glades Cunties AUXILIARY AID AND SERVICES PLAN January 2017, Revised- All Rights Reserved N part f this dcument may be reprduced r distributed in any frm r by any means,
More informationElectrosurgical Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc
Electrsurgical Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc Grwing awareness regarding mst recent surgical techniques in develping regins is expected
More informationBuilding Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing
Building Cde 101 OWMC Nvember 20, 2015 Ministry f Municipal Affairs and Husing Disclaimer These slides are prvided by the Ministry f Municipal Affairs and Husing fr cnvenience nly The slides shuld nt be
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationHearing Service Fees and Fee Codes Effective: January 01, 2019
Hearing Fees and Fee Cdes Effective: January 01, 2019 The WCB will fund the fllwing hearing services fr claims accepted fr traumatic and ccupatinal nise induced hearing: Fee cde 200 - Full audilgical assessment.
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationINSTALLATION AND OPERATING INSTRUCTIONS YD30 COBALT
INSTALLATION AND OPERATING INSTRUCTIONS YD30 COBALT CONTENTS 1. DESCRIPTION Pg. 2 2. PRODUCT UNBOXED Pg. 2 3. DIMENSIONS 3.1. Lck 3.2. Strike Plate 3.3. Fitting Tab 3.4. Husing 3.5. Dress Plate Pg. 3 3
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationSusan Wortman, Career Development Center
Susan Wrtman, Career Develpment Center Audience CV Résumé Fellw academics in yur field f study A general audience f emplyers wh hire fr a wide variety f psitins Gal T present yur full academic histry including
More information